Eric Nuermberger, MD

Faculty

Titles:

Associate Professor, Medicine

Email:

Eric Nuermberger

SciVal:

SciVal Link

The primary research focus in my laboratory is translational research related to TB drug development. Using established animal and in vitro models of active and latent TB infection and relying on pharmacodynamic principles, our major goal is to identify and optimize new drugs and drug combinations to shorten and/or simplify TB treatment and restrict the emergence of drug resistance. Over the past 15 years, our work has informed the development of a number of new and repurposed drugs, including moxifloxacin, rifapentine, bedaquiline, PA-824, and the oxazolidinones sutezolid and linezolid, as well as novel combinations containing these drugs. We continue to refine existing models and develop new models for pre-clinical drug efficacy studies, including murine models of cavitary TB and a flow-controlled in vitro system for studying the pharmacodynamics of new drugs and combinations.    

A second research interest is applying similar approaches to improve the treatment of Buruli ulcer, an emerging yet neglected tropical disease characterized by enlarging and ultimately disabling skin ulcers caused by infection with Mycobacterium ulcerans and production of its unique cytotoxin mycolactone. Only in the last decade has chemotherapy replaced surgery as the preferred therapeutic option, especially for early lesions. However, early lesions are difficult to detect with available diagnostics and the current regimen of streptomycin and rifampin for 8 weeks has many drawbacks. We aim to translate advances in the TB drug development space and novel ideas for detection of mycolactone in biological samples to improve therapeutics and point-of-care diagnostics.

Categories

Events

«

May 2017

»
S
M
T
W
T
F
S
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·

Projects

Understanding the role of repeat testing and...

We have developed a Markov model of serial IGRA testing to help improve testing algorithms with TST vs. IGRA in low-risk...

Read More

Modeling to improve TB decision-making in the...

We are part of a large consortium that is constructing epidemic and economic models of TB and HIV in collaboration with the U.S....

Read More

Modeling the impact of novel TB drug regimens...

We are constructing mathematical models of TB epidemics in Southeast Asia, India, and Vietnam to explore the potential...

Read More

Evaluating an automated system for...

We are evaluating the accuracy and cost-effectiveness of TBDx, an automated digital microscopy system, as a screening test to...

Read More

mHealth for improved TB contact investigation...

This multicenter randomized study is evaluating the implementation, effectiveness, cost-effectiveness, and population-level...

Read More